Clinical Trials

264 enrolled

Nasopharyngeal Carcinoma

NCT04436965 2026-05-11

Effect of Standard Nutrition Therapy on Nutritional Status and Prognosis in Locoregionally Advanced Nasopharyngeal Carcinoma Patients With Malnutrition

266 enrolled

Nasopharyngeal Carcinoma

NCT05340491 2026-05-11

Chemoradiotherapy Plus Anti-PD1 in Recurrent NPC: A Multicenter, Open-label, Randomised, Controlled, Phase III Trial

212 enrolled

Nasopharyngeal Carcinoma

NCT05780372 2026-05-11

Reduced Volume of Neck Prophylactic Irradiation in Nasopharyngeal Carcinoma

474 enrolled

Nasopharyngeal Carcinoma

NCT05941741 2026-05-11

IC Plus Low-dose Radiation Plus Cadonilimab in LANPC

380 enrolled

Nasopharyngeal Carcinoma

NCT05294172 2026-05-08

KL-A167 Injection Combined With Cisplatin and Gemcitabine vs Placebo Combined With Cisplatin and Gemcitabine in the Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma

295 enrolled

Nasopharyngeal Carcinoma, Neoplasm Metastasis, Recurrence

NCT02973386 2026-05-07

Prognostic Analysis of Concurrent Chemoradiotherapy With/Without Adjuvant Chemotherapy for Locally Advanced NPC Patients

Phase 3 Completed

294 enrolled

Nasopharyngeal Carcinoma

NCT03907826 2026-05-07

PD-1 Antibody Combined With Chemoradiotherapy in Recurrent Nasopharyngeal Carcinoma Patients

212 enrolled

Nasopharyngeal Carcinoma

NCT04944914 2026-04-30

Camrelizumab Plus Stereotactic Body Radiotherapy vs Camrelizumab Alone For Oligometastatic Nasopharyngeal Carcinoma

188 enrolled

Nasopharyngeal Carcinoma

NCT02633202 2026-04-24

Concurrent Chemotherapy for the Intermediate Risk Nasopharyngeal Carcinoma In Intensity-modulated Radiotherapy Era

Phase 3 Completed

338 enrolled

Nasopharyngeal Carcinoma

NCT07540390 2026-04-22

GAPP Induction and Concurrent Chemoradiotherapy for High-risk Locoregionally Advanced NPC.

442 enrolled

Nasopharyngeal Carcinoma

NCT06118333 2026-04-17

A Study Comparing BL-B01D1 With Physician's Choice of Chemotherapy in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma(PANKU-NPC01)

386 enrolled

Nasopharyngeal Carcinoma

NCT07201337 2026-04-06

Reduced-dose vs Standard-dose Irradiation for Low-risk Clinical Target Volume in Nasopharyngeal Carcinoma.

700 enrolled

Nasopharyngeal Carcinoma

NCT07459296 2026-03-16

Becotatug Vedotin Plus Sintilimab in Locoregionally Advanced NPC

266 enrolled

Nasopharyngeal Carcinoma

NCT06239727 2026-03-06

Reduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment Response

593 enrolled

Nasopharyngeal Carcinoma

NCT07327216 2026-03-04

Sapylin Versus Dexamethasone Inhalation for CCRT-Induced Oral Mucositis in Nasopharyngeal Carcinoma

180 enrolled

Nasopharyngeal Carcinoma

NCT06976190 2026-01-20

Magic-C002

446 enrolled

Nasopharyngeal Carcinoma, Recurrence

NCT07340515 2026-01-14

Proton vs Photon IMRT in Locally Advanced Nasopharyngeal Carcinoma: A Phase III Trial

300 enrolled

Nasopharyngeal Carcinoma

NCT07328841 2026-01-09

Reduced-dose Versus Conventional-dose Intensity-modulated Radiation Therapy for Locally Advanced Nasopharyngeal Carcinoma With Remission After Induction Chemotherapy and Immunotherapy

456 enrolled

Nasopharyngeal Carcinoma, Pathologic Complete Response

NCT07328854 2026-01-09

40.2Gy Versus 49.2Gy Radiotherapy in Low-Risk Target Volume for Chemosensitive Stage II Nasopharyngeal Carcinoma

346 enrolled

Nasopharyngeal Carcinoma, Pathologic Complete Response

NCT07303023 2025-12-24

INCIPT-NPC

462 enrolled

Nasopharyngeal Carcinoma

NCT07188584 2025-12-09

Phase III Non-Inferiority Trial: Reduced-Target vs. Full-Target IMRT After Chemo in Immunotherapy-Treated Metastatic Nasopharyngeal Cancer

166 enrolled

Nasopharyngeal Carcinoma

NCT07248670 2025-11-25

Concurrent Chemoradiotherapy With or Without Metronomic Capecitabine in High-Risk T1-2N1M0 NPC

252 enrolled

Nasopharyngeal Carcinoma

NCT04458909 2025-10-03

Testing the Addition of an Anti-cancer Immune Therapy Drug (Nivolumab) to the Usual Chemotherapy Treatment (Cisplatin or Carboplatin With Gemcitabine) for Recurrent or Metastatic Nasopharyngeal Cancer

Phase 3 Terminated

15 enrolled 17 charts

Nasopharyngeal Carcinoma

NCT06241612 2025-09-17

Individualized Elective Neck Irradiation in NPC Patients

470 enrolled

Nasopharyngeal Carcinoma

NCT04384627 2025-09-04

NPC-GTV

445 enrolled

Nasopharyngeal Carcinoma

NCT02363400 2025-08-19

A Phase III Trial in NPC With Post-radiation Detectable Plasma EBV DNA

Phase 3 Terminated

10 enrolled

Nasopharyngeal Carcinoma, Epstein-Barr Virus Infections

NCT06177301 2025-08-14

Tislelizumab Plus GX Versus Tislelizumab Plus GP in the Treatment of R/M NPC

266 enrolled

Nasopharyngeal Carcinoma

NCT07072000 2025-07-18

Shrinking the Anterior Border of CTV2 for Nasopharyngeal Carcinoma to Reduce the Radiation of Nasal Cavity

550 enrolled

Nasopharyngeal Carcinoma

NCT04907370 2025-07-16

DIAMOND

532 enrolled

Nasopharyngeal Carcinoma

NCT06228079 2025-07-04

Adjuvant vs Surgery Only in Early-stage Recurrent NPC

176 enrolled

Nasopharyngeal Carcinoma

NCT06235203 2025-06-03

Neoadjuvant vs Adjuvant in Locally Advanced Recurrent NPC

154 enrolled

Nasopharyngeal Carcinoma

NCT07000643 2025-06-03

Phase III Non-Inferiority Trial of Proton Versus Photon Therapy for Nasopharyngeal Carcinoma

386 enrolled

Nasopharyngeal Carcinoma

NCT04456322 2025-05-14

Radiotherapy Plus Nimotuzumab or Cisplatin in Nasopharyngeal Carcinoma

381 enrolled

Nasopharyngeal Carcinoma

NCT04974398 2025-04-13

A Study of Penpulimab (AK105) in the First-line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma

296 enrolled 1 FDA

Nasopharyngeal Carcinoma

NCT06752239 2025-04-10

PROTECT-NPC

474 enrolled

Nasopharyngeal Carcinoma, Radiation Injuries, Thyroid Diseases

NCT06900218 2025-04-02

PD-1 Antibody Sintilimab Combined With Capecitabine as Adjuvant Therapy for High-Risk Nasopharyngeal Carcinoma

664 enrolled

Nasopharyngeal Carcinoma

NCT05304468 2025-03-21

Reduced-dose Versus Standard Dose Radiotherapy for Nasopharyngeal Carcinomain

452 enrolled

Nasopharyngeal Carcinoma

NCT06712888 2025-03-18

Navigation

466 enrolled

Nasopharyngeal Carcinoma

NCT06629597 2025-02-10

A Phase III Study of YL201 in Recurrent or Metastatic Nasopharyngeal Carcinoma

400 enrolled

Nasopharyngeal Carcinoma

NCT05587374 2025-01-23

GEMSTONE

490 enrolled

Nasopharyngeal Carcinoma, Nasopharyngeal Neoplasms

NCT06775756 2025-01-15

Reducing Dose and Irradiated Volume in Cervical Prophylactic Irradiation for Nasopharyngeal Cancer

474 enrolled

Nasopharyngeal Carcinoma

NCT03840421 2025-01-13

GP Vs PF As Induction Chemotherapy Combined with CCRT for Locoregionally Advanced Nasopharyngeal Carcinoma

468 enrolled

Nasopharyngeal Carcinoma, Head and Neck Neoplasms, Nasopharyngeal Diseases, Nasopharyngeal Neoplasms

NCT05869227 2024-12-30

Maintenance Therapy With Toripalimab Combined With Capecitabine/Placebo for Recurrent and Metastatic Nasopharyngeal Carcinoma

166 enrolled

Nasopharyngeal Carcinoma

NCT02460887 2024-12-03

The Role of Induction Gemcitabine and Cisplatin in Locoregionally Advanced Nasopharyngeal Carcinoma in the Era of IMRT

236 enrolled

Nasopharyngeal Carcinoma

NCT06675214 2024-11-05

Under Whole-course of Immunotherapy, Gradient Fractionated RT with CCT Versus CFRT with CCT for LANPC Who Achieved PR Post Induction Chemotherapy.

586 enrolled

Nasopharyngeal Carcinoma

NCT05979961 2024-08-06

Phase III Trial of Concurrent Chemotherapy Alone in Patients With Low-risk Nasopharyngeal Carcinoma

454 enrolled

Nasopharyngeal Carcinoma

NCT06516133 2024-07-23

OART

494 enrolled

Nasopharyngeal Carcinoma

NCT06383780 2024-07-16

Tislelizumab in Combination With GP or TPC Regimen for the Treatment of Nasopharyngeal Carcinoma With Bone Metastasis.

90 enrolled